HUP0303695A2 - Módosított hatóanyag-leadású metil-fenidát készítmények és eljárás az elõállításukra - Google Patents

Módosított hatóanyag-leadású metil-fenidát készítmények és eljárás az elõállításukra

Info

Publication number
HUP0303695A2
HUP0303695A2 HU0303695A HUP0303695A HUP0303695A2 HU P0303695 A2 HUP0303695 A2 HU P0303695A2 HU 0303695 A HU0303695 A HU 0303695A HU P0303695 A HUP0303695 A HU P0303695A HU P0303695 A2 HUP0303695 A2 HU P0303695A2
Authority
HU
Hungary
Prior art keywords
methylphenidate
preparation
release formulations
modified release
release
Prior art date
Application number
HU0303695A
Other languages
English (en)
Inventor
Marie J. Bettman
Dan L. Hensley
Phillip J. Percel
Gopi M. Venkatesh
Krishna S. Vishnupad
Original Assignee
Celltech Manufacturing Ca, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24802604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0303695(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech Manufacturing Ca, Inc. filed Critical Celltech Manufacturing Ca, Inc.
Publication of HUP0303695A2 publication Critical patent/HUP0303695A2/hu
Publication of HUP0303695A3 publication Critical patent/HUP0303695A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Abstract

A találmány tárgyát módosított hatóanyag-leadású metilfenidáthidroklorid kapszula hatóanyag-szállító rendszer képezi, amelykapszulákba töltve azonnali hatóanyag-leadású, azaz IR- és elnyújtotthatóanyag-leadású, azaz ER-gyöngyök sokaságát tartalmazza 10lR/90ER-50lR/50ER arányban és az IR- és ER- gyöngyök mindegyike 5-20 tömeg%metil-fenidát-hidrokloridot tartalmaz. A találmány tárgyát képezitovábbá eljárás az említett hatóanyag-szállító rendszer előállítására. Ó
HU0303695A 2000-10-27 2001-10-09 Methylphenidate modified release formulations and process for their preparation HUP0303695A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/697,803 US6344215B1 (en) 2000-10-27 2000-10-27 Methylphenidate modified release formulations
PCT/US2001/042561 WO2002034234A2 (en) 2000-10-27 2001-10-09 Methylphenidate modified release formulations

Publications (2)

Publication Number Publication Date
HUP0303695A2 true HUP0303695A2 (hu) 2004-03-01
HUP0303695A3 HUP0303695A3 (en) 2010-03-29

Family

ID=24802604

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303695A HUP0303695A3 (en) 2000-10-27 2001-10-09 Methylphenidate modified release formulations and process for their preparation

Country Status (13)

Country Link
US (1) US6344215B1 (hu)
EP (4) EP2286815A3 (hu)
JP (1) JP2004512296A (hu)
AU (2) AU9701101A (hu)
CA (1) CA2426883C (hu)
CY (1) CY1118946T1 (hu)
DK (1) DK2103307T3 (hu)
ES (1) ES2618603T3 (hu)
HU (1) HUP0303695A3 (hu)
NO (1) NO20031843L (hu)
PL (1) PL203828B1 (hu)
PT (1) PT2103307T (hu)
WO (1) WO2002034234A2 (hu)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
NZ511442A (en) * 1998-11-02 2003-02-28 Elan Corp Plc Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
KR101167465B1 (ko) 2000-10-30 2012-07-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
CA2447008A1 (en) * 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
HUE026034T2 (hu) 2002-12-13 2016-05-30 Durect Corp Magas viszkozitású hordozóanyagot tartalmazó szájon át beadandó hatóanyag-szállító rendszer
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
ES2534827T3 (es) 2003-04-07 2015-04-29 Supernus Pharmaceuticals, Inc. Formulaciones de tetraciclinas en dosis única diaria
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
AR046410A1 (es) * 2003-09-18 2005-12-07 Cephalon Inc Composiciones farmaceuticas para la liberacion modificada de modafinilo
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
ES2261006B1 (es) 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) * 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP1802285B1 (en) 2004-10-21 2013-02-27 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
US20060127421A1 (en) * 2004-12-09 2006-06-15 Celgene Corporation Treatment using D-threo methylphenidate
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EA200702221A1 (ru) * 2005-04-12 2008-04-28 Элан Фарма Интернэшнл Лимитед Композиции с контролируемым высвобождением для лечения бактериальной инфекции, содержащие цефалоспорин
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
WO2007109104A2 (en) 2006-03-16 2007-09-27 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
CN101453996B (zh) * 2006-04-03 2016-05-11 伊萨·奥迪迪 药物递送组合物
WO2008011596A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
CA2618240C (en) 2006-11-17 2015-01-20 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
CN102218044A (zh) * 2006-12-04 2011-10-19 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
WO2009088414A2 (en) 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
MX2010008138A (es) 2008-01-25 2010-08-10 Gruenenthal Gmbh Forma de dosis farmaceutica.
TW200940110A (en) * 2008-02-22 2009-10-01 Astrazeneca Ab Pharmaceutical formulation comprising oxabispidines
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
EP2368546A4 (en) * 2008-11-07 2013-11-20 Samyang Biopharmaceuticals PHARMACEUTICAL COMPOSITION WITH PROGRESSIVE RELEASE OF METHYLPHENIDATE
MX2019001413A (es) 2008-12-19 2019-08-12 Supernus Pharmaceuticals Inc Uso de molindona para el tratamiento de agresion.
EP3045043B1 (en) 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
AR077493A1 (es) 2009-07-22 2011-08-31 Gruenenthal Gmbh Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion
WO2011020032A2 (en) * 2009-08-13 2011-02-17 Kudco Ireland, Ltd. Pharmaceutical dosage form
AU2010325746B2 (en) 2009-12-02 2016-02-25 Adare Pharmaceuticals S.R.L. Fexofenadine microcapsules and compositions containing them
TW201127375A (en) * 2010-01-08 2011-08-16 Eurand Inc Taste masked topiramate composition and an orally disintegrating tablet comprising the same
ES2756711T3 (es) 2010-03-31 2020-04-27 Supernus Pharmaceuticals Inc Formulaciones estabilizadas de compuestos del SNC
AR082862A1 (es) 2010-09-02 2013-01-16 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
CN101933913A (zh) * 2010-09-16 2011-01-05 孙卫东 一种盐酸右哌甲酯双释放制剂及其制备方法
US8287903B2 (en) * 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
CA2830788C (en) * 2011-03-23 2016-05-17 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
WO2013003622A1 (en) * 2011-06-28 2013-01-03 Neos Therapeutics, Lp Dosage forms for oral administration and methods of treatment using the same
KR20140053159A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
NO2736497T3 (hu) 2011-07-29 2018-01-20
FR2983197B1 (fr) * 2011-11-29 2014-07-25 Assist Publ Hopitaux De Paris Utilisation de phacetoperane pour traiter un trouble deficit de l'attention hyperactivite
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
WO2014174388A1 (en) 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
CA2936741C (en) * 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US20170296476A1 (en) * 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP2020504763A (ja) * 2016-11-01 2020-02-13 ネオス・セラピューティクス・エルピー メチルフェニデートを用いてａｄｈｄを処置するための小児の有効な投薬
EP3372225A1 (en) * 2017-03-09 2018-09-12 Develco Pharma Schweiz AG Novel dosage form
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US20190110992A1 (en) 2017-10-13 2019-04-18 Grünenthal GmbH Modified release abuse deterrent dosage forms
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB906422A (en) 1958-05-02 1962-09-19 Wellcome Found Improvements in and relating to prolonged acting pharmaceutical preparations
US3558768A (en) 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
SE457326B (sv) 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5500227A (en) 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6289204B1 (en) * 1998-07-09 2001-09-11 Motorola, Inc. Integration of a receiver front-end in multilayer ceramic integrated circuit technology
NZ511442A (en) * 1998-11-02 2003-02-28 Elan Corp Plc Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
AU4334700A (en) * 1999-04-06 2000-10-23 Shubha Chungi Pharmaceutical dosage form for pulsatile delivery of methylphenidate
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations

Also Published As

Publication number Publication date
EP2103307A2 (en) 2009-09-23
US6344215B1 (en) 2002-02-05
WO2002034234A3 (en) 2002-12-05
EP2269605A3 (en) 2011-06-29
CA2426883A1 (en) 2002-05-02
EP2103307B1 (en) 2016-12-07
PT2103307T (pt) 2017-03-14
EP2103307B9 (en) 2017-03-01
CA2426883C (en) 2010-08-24
ES2618603T3 (es) 2017-06-21
HUP0303695A3 (en) 2010-03-29
NO20031843D0 (no) 2003-04-24
CY1118946T1 (el) 2018-01-10
AU2001297011B2 (en) 2007-03-15
WO2002034234A2 (en) 2002-05-02
EP2286815A2 (en) 2011-02-23
PL203828B1 (pl) 2009-11-30
EP2103307A3 (en) 2010-04-28
EP2269605A2 (en) 2011-01-05
JP2004512296A (ja) 2004-04-22
PL361673A1 (en) 2004-10-04
EP1328251A2 (en) 2003-07-23
AU9701101A (en) 2002-05-06
DK2103307T3 (en) 2017-03-13
NO20031843L (no) 2003-04-24
EP2286815A3 (en) 2011-06-29

Similar Documents

Publication Publication Date Title
HUP0303695A2 (hu) Módosított hatóanyag-leadású metil-fenidát készítmények és eljárás az elõállításukra
KR101834033B1 (ko) 주의력 결핍 장애 치료용 고체 경구 제약 조성물
DK1909766T3 (en) PHARMACEUTICAL FORMULATIONS / FORMATIONS OF guanfacine SUITABLE FOR DAILY ADMINISTRATION IN SINGLE DOSE FORM
AU1227899A (en) Osmotic medicament releasing system
HU229312B1 (hu) Szabályozott hatóanyag-leadású gyógyszer-dózisformák legalább egy idõzített gyors szakaszt magába foglaló szabályozott hatóanyag-leadásra
TW200738228A (en) Neramexane modified release matrix tablet
US10182995B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
NO20071044L (no) Doseformer med enteraltbelagte tablettkjerner
US8927010B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US10722511B2 (en) Treating pain in patients with hepatic impairment
US20110313046A1 (en) Combination therapy with lisdexamphetamine and extended release guanfacine
US9283214B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) Methods of treatment of attention deficit hyperactivity disorder
JP2014005310A (ja) ナルトレキソンの徐放型配合物
Venkatesh et al. Development of orally disintegrating tablets comprising controlled-release multiparticulate beads
HUP0104647A2 (hu) Hatóanyagként tilidin-mezilátot tartalmazó, szabályozott hatóanyag-leadású gyógyszerkészítmény
US10292937B2 (en) Methods of treatment of attention deficit hyperactivity disorder
US20230218552A1 (en) Acetaminophen Formulation With Protection Against Toxic Effects of Overdose
US20220110878A1 (en) Compositions for Treatment of Attention Deficit Hyperactivity Disorder
CA2872677A1 (en) Treating pain in patients with hepatic impairment
US10905652B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
Liu et al. Review and comparison of the long acting methylphenidate preparations
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
MXPA01008348A (es) Microcapsulas para la liberacion prolongada de farmacos.
EP3461476A1 (en) Delayed-release tablets of methylphenidate

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished